News / Korea / yonhap_finance
Sejong Medical and Genencell Face Stock Manipulation Allegations Amid Insider Trading Probe
Health Technology · Biotechnology · yonhap_finance · 2026-09-09
Allegations of insider trading and stock manipulation involving Sejong Medical and Genencell have left retail investors facing massive losses and delisting.
What Happened
Unfair Trading Allegations: Investigations into a former ministerial candidate have uncovered evidence of insider trading between Genencell and Sejong Medical. The founder of Genencell allegedly shared non-public information regarding a stake acquisition with associates to profit from subsequent stock price movements.
Manipulation Tactics: Sejong Medical allegedly used false clinical trial data and aggressive business expansion claims to artificially inflate its stock price. Following the announcement of clinical trial approvals, early investors offloaded significant holdings, causing the share price to collapse and leaving retail investors holding the bag.
Retail Investor Impact: The stock price plummeted shortly after the clinical news, eventually leading to a trading suspension and potential delisting for Sejong Medical. Approximately 700 retail shareholders, who invested based on the inflated expectations, are now seeking legal recourse for their substantial financial losses.
Regulatory Concerns: The case highlights the persistent issue of market manipulation and the exploitation of retail investors by sophisticated trading groups in the Korean market. Experts are calling for stricter penalties and more robust enforcement to deter capital market crimes and protect individual investors.